logo
Apple iPhone 17 event — rumored date and all the new products expected to launch

Apple iPhone 17 event — rumored date and all the new products expected to launch

Yahoo2 days ago
When you buy through links on our articles, Future and its syndication partners may earn a commission.
Apple's next iPhone event is right around the corner. While the company has yet to confirm the date and time for its major fall product launch, rumors say the date is Tuesday, September 9.
As with most big Apple launches, we expect the event to take place at the company's Cupertino campus, where the iPhone 17 series will be revealed. This year could shake up the iPhone lineup with the Plus model replaced by the super-thin iPhone 17 Air.
The phones won't be alone, though. In addition to the iPhone 17 and iPhone 17 Pro, we expect to see the debut of the Apple Watch Series 11 and possibly the Apple Watch Ultra 3. There are a couple of long-shot products that are supposed to debut this Fall that could show up in September, including an updated Apple TV 4K and the long-awaited smart home hub HomePod 3.
When is the September 2025 Apple event?
The event has not yet been officially confirmed. Rumors say it will take place on September 9, 2025.
Apple typically sends invitations about two weeks before the official date. With that in mind, we expect to see official invites around August 25.
Last year's event started at 10 a.m. PT/ 1 p.m. ET / 6 p.m. BST, and we imagine this year's event will take place at a similar time.
Apple shares event livestreams on its YouTube channel, Apple.com, and on Apple TV. Apple Vision Pro users should also be able to watch on their headset.
iPhone 17
As always in the September event is headlined by the iPhone. We're expecting the iPhone 17 series, which should include four total devices: iPhone 17, iPhone 17 Air, iPhone 17 Pro, and iPhone 17 Pro Max.
Normally, we'd share pricing rumors here, but those have been hard to pin down, especially with President Trump's instituted tariffs and threatened ones against companies like Apple. The company recently announced a $100 billion investment in US manufacturing, likely to prevent some tariffs from hitting its coffers even more.
Last year, Apple didn't raise the prices on the iPhone 16 models, which started at $799. However, the iPhone 16e, released in the spring, did see a $179 bump from its iPhone SE predecessor.
Unfortunately, some analysts suggest that a major price hike is coming this year.
Beyond that, the vanilla iPhone 17 may feature a larger 6.3-inch 120Hz ProMotion display, which would put it on par with the Pro models. Every new iPhone should feature the A19 chipset, which could be built with a 3nm process, meaning greater transistor density for better performance and efficiency. There are rumors that the standard model will feature an A18 chipset.
iPhone 17 Air
The big departure this year will be the Plus model, which could be replaced by the much-rumored ultra-thin iPhone 17 Air. The Air would be a premium handset that could be as thin as 5.65mm (slightly thinner than the also super-slim 5.8mm Samsung Galaxy S25 Edge).
It could feature a 6.6-inch screen, a tad smaller than the 6.7-inch display on the iPhone 16 Plus. The skinny device could also be limited to a 2,800mAh battery, but new silicon-carbon technology could make it denser. As a more premium model, the price might exceed the $899 starting price of the Plus and sit closer to the $1,199 of the iPhone 16 Pro Max.
iPhone 17 Pro and Pro Max
Speaking of the Pro Max, the big design change we expect to see is a new rectangular camera array that spans the backside of the phone and is more reminiscent of the Google Pixel 9 Pro design. That new array should feature an upgraded 48MP telephone lens with a 3.5x optical zoom, replacing the current 12MP, 5x lens. Additionally, there may be an upgraded 24MP front-facing camera.
Apple is rumored to be working on a vapor cooling chamber that would replace the standard heatsinks currently available. That new cooling feature is rumored to only come to the Pro models.
With updates to Qi2 wireless charging, it's likely the iPhone 17 lineup could see charging speeds up to 35W.
The big update for all four handsets will be the fully released iOS 26 software, which we've been previewing in the ongoing beta program. Apple Intelligence isn't the main focus this year, but there is a suite of AI tools coming with iOS 26. And then there's the somewhat controversial Liquid Glass aesthetics.
Apple Watch Series 11 and Watch Ultra 3
The other product we're fairly certain will debut is the Apple Watch Series 11. There should be a number of chip updates for the Watch 11. MacRumors reports that an updated S11 chip with a compact design should arrive alongside a new MediaTek modem chip, which would bring 5G connectivity to the Apple Watch, a boost over current LTE options.
The big upgrade would be a version of blood pressure monitoring. This monitor would only measure blood pressure and provide an alert if hypertension is detected. There are rumors that Blood Oxygen monitoring is coming, though Apple is still fighting its lawsuit with Masimo, so that may not happen.
watchOS 26 is set to release in September with new features that include wrist flick gestures, smarter notifications, the Notes App, and an AI-powered 'Workout Buddy' that acts as a coach for your exercise.
The watch could cost $399, the same as the current Apple Watch Series 10, but again, tariffs could affect it.
Multiple reports have suggested that the Apple Watch Ultra 3 will finally launch this year as a long-awaited follow-up to the Apple Watch Ultra 2. Beyond new wellness features and a new chip, we don't know what other upgrades or design changes it will offer. Some rumors have hinted at a wide-angle OLED display that is slightly larger. It also might get satellite connectivity, which would enable emergency text messages. A similar feature debuted in iOS 18 for iPhones.
Lastly, we expect the entry-level Apple Watch SE 3 to arrive this year, so that could make an appearance.
AirPods Pro 3
Accessories usually arrive during Apple's fall event, and we expect this year to be no different. Last year saw the release of the Apple AirPods 4. The AirPods Pro 3 didn't arrive, but are rumored to come out this year.
The headphones are due for a refresh with the AirPods Pro 2 being introduced in 2022, only seeing a USB-C update in 2023. They should cost a similar $250 as the most expensive in-ear headphones that Apple produces.
Rumors suggest that Apple may put a touchscreen on the charging case and a heart monitor in the buds themselves, and there may be additional sensors for more health tracking. Lastly, the controls on the in-ears could change to more conventional swipes and taps rather than capacitive squeezes.
Longshots: Apple TV 4K & HomePod 3
Both an updated Apple TV 4K streaming device and an overhauled HomePod 3 speaker or smart home hub could be revealed during the event. Both reportedly could launch sometime in the latter half of 2025, though it's just as likely that they won't arrive until October or November.
The HomePod 3 is supposed to kickstart a big push into smart home integration, which would integrate with the new Apple TV box. Some wilder ideas include Apple introducing a built-in camera to the box, which was teased by tvOS 17, and adding a FaceTime app.
The HomePod 3 was reportedly delayed as Apple struggled to get Apple Intelligence and an improved Siri together because it would utilize Siri and AI to control other smart devices. It also may feature an iPad-like display, making it more reminiscent of the Amazon Echo Show 15.
Apple could hold a second event in the fall for both devices and its new Mac releases.
Keep Tom's Guide in your tabs for full coverage of the iPhone 17 launch as it happens in September.
Follow Tom's Guide on Google News to get our up-to-date news, how-tos, and reviews in your feeds. Make sure to click the Follow button.
More from Tom's Guide
iOS 26 will bring GPT-5 to Apple Intelligence — what you need to know
Your Apple Watch finally has the Notes app — here's how to unlock it
I biked 11 miles with the Apple Watch 10 vs Garmin Forerunner 570 — here's the winner
Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

Newton Golf Company Reports Second Quarter 2025 Financial Results
Newton Golf Company Reports Second Quarter 2025 Financial Results

Yahoo

time7 minutes ago

  • Yahoo

Newton Golf Company Reports Second Quarter 2025 Financial Results

Revenue Climbs 154% Year-over-Year as Tour Adoption and Product Momentum Accelerate CAMARILLO, Calif., Aug. 14, 2025 (GLOBE NEWSWIRE) -- via IBN – Newton Golf Company (NASDAQ: NWTG) ('Newton Golf' or the 'Company'), a technology-forward golf company delivering physics-based performance innovations, today announced financial results for the second quarter ended June 30, 2025. Second Quarter and Year-to-Date 2025 Highlights Q2 2025: Revenue increased 154% year-over-year to $2.1 million, compared to $813,000 in Q2 2024 First Six Months 2025: Revenue increased 182% year-over-year to $3.3 million, compared to $1.2 million in the first half of 2024 Q2 2025: Gross profit rose 186% to $1.4 million, up from $489,000 in Q2 2024 First Six Months 2025: Gross profit increased 224% to $2.3 million, up from $695,000 in the first half of 2024 Q2 2025: Gross margin improved to 67.6%, compared to 60.1% in Q2 2024 First Six Months 2025: Gross margin expanded to 68.7%, compared to 59.8% in the first half of 2024 Q2 2025: Net loss of $1.5 million, or ($0.34) per share, compared to a net loss of $1.2 million, or ($0.79) per share, in Q2 2024 First Six Months 2025: Net loss of $2.1 million, or ($0.74) per share, compared to a net loss of $2.4 million, or ($1.61) per share, in the first half of 2024 Cash & Equivalents: $4.0 million as of June 30, 2025 Management Commentary Greg Campbell, CEO: "Our Q2 results highlight continued progress across multiple channels, with strong performance from our Motion and Fast Motion shafts, growing adoption among tour professionals, and expanding relationships with global distributors. We also increased our marketing and sales investments this quarter to build on that momentum heading into the second half of the year." Jeff Clayborne, CFO: "It's an exciting time to join Newton Golf as we build both financial momentum and market presence. In Q2, we delivered meaningful top-line growth and maintained solid margins, supported by strong product demand and operational efficiency. We remain focused on disciplined execution as we scale, and confident in our ability to drive long-term value for shareholders." Recent Business Highlights Miguel Ángel Jiménez earned his second PGA TOUR Champions victory using the Newton Fast Motion shaft Launched on April 29, 2025, the Newton Fast Motion golf shaft has surged to become a breakout success in just its first months on the market. In May and June alone, 1,817 units generated over $696,000 in gross sales, and momentum only accelerated into Q3 with 2,211 units sold to date, producing more than $786,000 in revenue. This rapid adoption—outpacing even the established Motion line—underscores the Fast Motion's powerful market appeal, exceptional performance, and the strong demand from golfers seeking the next leap in shaft innovation. Newton's newest release is not just gaining traction—it's redefining the speed at which a premium golf shaft can capture market share. Newton surpassed 50 professional users across PGA TOUR Champions, LPGA, and Korn Ferry Tours Increased production capacity to meet accelerating demand for Motion and Fast Motion shafts Experienced significant growth in direct-to-consumer sales through Expanded distribution and product testing with international fitters and retailers, including new partnerships in Japan Newton shaft technology was highlighted by Golf Magazine's Kris McCormack as one of the most exciting new shaft innovations on the market 2025 Revenue Guidance The Company is raising its full-year 2025 revenue guidance to a range of $7.0 million to $7.5 million, up from the prior range of $6.5 million to $7.0 million issued last quarter, reflecting stronger-than-anticipated demand and continued momentum across key channels. Looking Ahead 'As we move into the second half of 2025, our focus is on scaling operations and deepening product adoption,' added Campbell. 'With new products on the horizon and expanded retail partnerships underway, we remain committed to building a differentiated, performance-driven brand.' Consolidated Results of Operations (Amounts rounded to nearest thousands, except share amounts) Three Months Ended June 30, Six Months Ended June 30, 2025 2024 2025 2024 Net Sales $ 2,068,000 $ 813,000 $ 3,278,000 $ 1,163,000 Cost of goods sold 669,000 324,000 1,027,000 468,000 Gross profit 1,399,000 489,000 2,251,000 695,000 Operating expenses Selling, general and administrative expenses 2,763,000 1,484,000 5,304,000 2,755,000 Research and development 143,000 207,000 425,000 397,000 Total operating expenses 2,906,000 1,691,000 5,729,000 3,152,000 Loss from operations (1,507,000 ) (1,202,000 ) (3,478,000 ) (2,457,000 ) Interest income, net 29,000 47,000 74,000 109,000 Change in fair value of warrant liabilities (42,000 ) - 1,359,000 - Net loss $ (1,520,000 ) $ (1,155,000 ) $ (2,045,000 ) $ (2,348,000 ) Loss per share – basic and diluted $ (0.34 ) $ (0.79 ) $ (0.74 ) $ (1.61 ) Weighted average number of shares outstanding – basic and diluted 4,509,619 1,459,587 2,778,595 1,459,587 For more information, visit the Company's investor relations website at or contact Investor Relations at ir@ Investor Alerts Stay updated with the latest from Newton Golf! Sign up for investor alerts at to receive company news and strategic developments directly to your inbox. About NEWTON GOLF At Newton Golf, we harness the power of physics to revolutionize golf equipment design. Formerly known as Sacks Parente, our rebranding reflects our commitment to innovation inspired by Sir Isaac Newton, the father of physics. By applying Newtonian principles to every aspect of our design process, we create precision-engineered golf equipment—including Newton Motion shafts and Gravity putters—that deliver unmatched stability, control, and performance. Our mission is to empower golfers with scientifically advanced tools that maximize consistency and accuracy, ensuring every swing is backed by the laws of physics. Forward-Looking Statements This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These statements relate to future events or the future financial performance of Newton Golf Company (the 'Company') and involve known and unknown risks, uncertainties, and other factors that may cause actual results, performance, or achievements to be materially different from any future results, performance, or achievements expressed or implied by the forward-looking statements. In some cases, forward-looking statements can be identified by terms such as "may," "will," "should," "expects," "plans," "anticipates," "intends," "believes," "estimates," "projects," "potential," "continues," or the negative of these terms or other comparable terminology. These forward-looking statements include, but are not limited to, statements regarding the expected benefits of the reverse stock split, the Company's ability to maintain compliance with Nasdaq listing requirements, the potential for increased institutional investor interest, the Company's future growth strategy, expansion of its product portfolio, anticipated financial performance, and future business prospects. These forward-looking statements reflect the Company's current expectations and projections based on information available as of the date of this release and are subject to a number of risks and uncertainties, including, but not limited to, general economic, financial, and business conditions; changes in consumer demand and industry trends; the Company's ability to successfully implement its strategic initiatives; competition in the golf equipment market; supply chain disruptions; regulatory compliance and legal proceedings; and other risks detailed from time to time in the Company's filings with the Securities and Exchange Commission (SEC), including its most recent Annual Report on Form 10-K and subsequent Quarterly Reports on Form 10-Q. The Company cautions investors that forward-looking statements are not guarantees of future performance and actual results may differ materially from those projected. The Company undertakes no obligation to update or revise any forward-looking statements, whether as a result of new information, future events, or otherwise, except as required by law. Media Contact: Beth GastBG Public Investor Contact: Scott McGowanInvestor Brand Network (IBN)Phone: 310.299.1717ir@ in to access your portfolio

Leap Therapeutics Reports Second Quarter 2025 Financial Results
Leap Therapeutics Reports Second Quarter 2025 Financial Results

Yahoo

time7 minutes ago

  • Yahoo

Leap Therapeutics Reports Second Quarter 2025 Financial Results

CAMBRIDGE, Mass., Aug. 14, 2025 /PRNewswire/ -- Leap Therapeutics, Inc. (Nasdaq:LPTX), a biotechnology company focused on developing targeted and immuno-oncology therapeutics, today reported financial results for the second quarter of 2025. Leap Highlights: Board of Directors initiated process of exploring strategic alternatives to maximize shareholder value Strategic restructuring to prioritize corporate development resulting in a further 75% reduction in workforce Reported updated data from the randomized, controlled Part B of the Phase 2 DeFianCe study of sirexatamab (DKN-01) plus bevacizumab and chemotherapy in second-line colorectal cancer (CRC) "This past quarter, we undertook a strategic realignment to focus our resources on corporate development opportunities for sirexatamab and FL-501," said Douglas E. Onsi, President and CEO of Leap Therapeutics. "As part of this effort, we completed patient treatment in the DeFianCe trial, further reduced internal expenses, and initiated a review of strategic alternatives to maximize value for our shareholders. We intend to provide a further update in the coming weeks. We are grateful to all of our team members, and we thank them for their important contributions to Leap and their commitment to developing new therapies for cancer patients." DKN-01 Development Update Reported updated clinical data from Part B of the DeFianCe study of sirexatamab plus bevacizumab and chemotherapy in CRC patients. In the updated analysis as of May 22, 2025, sirexatamab demonstrated a statistically significant benefit on overall response rate (ORR), by investigator assessment and blinded independent central review, and progression-free survival (PFS) in patients with high levels of DKK1, no prior exposure to anti-VEGF therapy, or liver metastasis, along with a positive trend on ORR and PFS in the full intent-to-treat population. The final data from the study is being prepared for presentation at a future medical conference. Business Updates Exploring strategic alternatives to preserve and maximize shareholder value. The Board of Directors initiated a process to explore strategic alternatives to preserve and maximize shareholder value, including leveraging its cash balance and exploring potential sale or partnership opportunities for sirexatamab and FL-501. The Company's Board of Directors has approved the engagement of Raymond James & Associates, Inc. to serve as exclusive financial advisor to assist in the strategic evaluation process. Taking additional steps to reduce spending and preserve capital. The Company implemented an additional workforce reduction of approximately 75%. The total costs related to this reduction in force, including severance payments, are estimated to be approximately $4.5 million. The majority of these costs will be recognized in the third and fourth quarters of 2025. Selected Second Quarter 2025 Financial Results Net Loss was $16.6 million for the second quarter 2025, compared to $20.4 million for the second quarter 2024. The decrease was primarily due to a decrease in research and development and general and administrative expenses, offset in part by a restructuring charge associated with the reduction in force. Research and development expenses were $10.5 million for the second quarter of 2025, compared to $17.9 million for the same period in 2024. The decrease of $7.4 million was primarily due to decreases of $3.9 million in clinical trial costs, $1.7 million in payroll and other headcount related expenses, $1.4 million in manufacturing costs, and $0.4 million in stock-based compensation expense. General and administrative expenses were $1.8 million for the second quarter 2025, compared to $3.4 million for the same period in 2024. The decrease of $1.6 million was primarily due to decreases of $1.4 million in payroll and other incentive based compensation expense and a $0.2 million decrease in stock-based compensation expense. During the second quarter of 2025, we incurred $4.5 million of restructuring charges associated with our workforce reduction, consisting primarily of one-time employee severance and benefit costs. Cash and cash equivalents totaled $18.1 million on June 30, 2025. About Leap TherapeuticsLeap Therapeutics (Nasdaq: LPTX) is focused on developing targeted and immuno-oncology therapeutics. Leap's pipeline includes sirexatamab (DKN-01), is a humanized monoclonal antibody targeting the Dickkopf-1 (DKK1) protein, and FL-501, a humanized monoclonal antibody targeting the growth and differentiation factor 15 (GDF-15) protein. For more information about Leap Therapeutics, visit or view our public filings with the SEC that are available via EDGAR at or via FORWARD-LOOKING STATEMENTSThis press release contains forward-looking statements within the meaning of the federal securities laws. Such statements are based upon current plans, estimates and expectations of the management of Leap that are subject to various risks and uncertainties that could cause actual results to differ materially from such statements. The inclusion of forward-looking statements should not be regarded as a representation that such plans, estimates and expectations will be achieved. Words such as "anticipate," "expect," "project," "intend," "believe," "may," "will," "should," "plan," "could," "continue," "target," "contemplate," "estimate," "forecast," "guidance," "predict," "possible," "potential," "pursue," "likely," and words and terms of similar substance used in connection with any discussion of future plans, actions or events identify forward-looking statements. All statements, other than historical facts, including statements regarding the potential safety, efficacy, and regulatory and clinical progress of Leap's product candidates, including sirexatamab and FL-501; Leap's plan to reduce clinical and operational activities, reduce spending and conserve cash, explore strategic alternatives to preserve and maximize shareholder value, including by leveraging its cash balance and potentially selling or partnering sirexatamab or FL-501; and any assumptions underlying any of the foregoing, are forward-looking statements. Important factors that could cause actual results to differ materially from Leap's plans, estimates or expectations could include, but are not limited to: (i) Leap's ability to successfully sell or enter into partnerships for sirexatamab or FL-501; (ii) the cost and timeline to complete the DeFianCe Study and wind-down operations; (iii) any regulatory feedback that Leap may receive from U.S. Food and Drug Administration (FDA) or equivalent foreign regulatory agency or from site institutional review boards; and (iv) the availability of strategic alternatives that would preserve or generate any shareholder value. New risks and uncertainties may emerge from time to time, and it is not possible to predict all risks and uncertainties. No representations or warranties (expressed or implied) are made about the accuracy of any such forward-looking statements. Leap may not actually achieve the forecasts disclosed in such forward-looking statements, and you should not place undue reliance on such forward-looking statements. Such forward-looking statements are subject to a number of material risks and uncertainties including but not limited to those set forth under the caption "Risk Factors" in Leap's most recent Annual Report on Form 10-K filed with the SEC, as well as discussions of potential risks, uncertainties, and other important factors in its subsequent filings with the SEC. Any forward-looking statement speaks only as of the date on which it was made. Neither Leap, nor any of its affiliates, advisors or representatives, undertake any obligation to publicly update or revise any forward-looking statement, whether as a result of new information, future events or otherwise, except as required by law. These forward-looking statements should not be relied upon as representing Leap's views as of any date subsequent to the date hereof. CONTACT: Douglas E. OnsiPresident & Chief Executive OfficerLeap Therapeutics, Inc.617-714-0360donsi@ Matthew DeYoungInvestor RelationsArgot Partners212-600-1902leap@ Leap Therapeutics, Inc. Condensed Consolidated Statements of Operations (In thousands, except share and per share amounts) (Unaudited)Three Months Ended June 30, Six Months Ended June 30, 2025202420252024 Operating expenses: Research and development$ 10,537$ 17,885$ 23,448$ 29,184 General and administrative 1,817 3,367 4,823 6,893 Restructuring charges 4,527 — 4,527 — Total operating expenses 16,881 21,252 32,798 36,077 Loss from operations (16,881) (21,252) (32,798) (36,077) Interest income 246 865 683 1,640 Interest expense (7) — (13) — Australian research and development incentives 1 253 56 499 Foreign currency gain (loss) (2) 6 (6) (10) Net loss$ (16,643)$ (20,128)$ (32,078)$ (33,948) Dividend attributable to down round feature of warrants — (234) — (234) Net loss attributable to common stockholders$ (16,643)$ (20,362)$ (32,078)$ (34,182)Net loss per share Basic and diluted$ (0.40)$ (0.52)$ (0.78)$ (1.01)Weighted average common shares outstanding Basic and diluted 41,444,979 39,122,662 41,357,423 33,830,083 Leap Therapeutics, Inc. Condensed Consolidated Balance Sheets (In thousands, except share and per share amounts)June 30, December 31, 20252024 Assets Current assets: Cash and cash equivalents$ 18,130$ 47,249 Research and development incentive receivable 739 704 Prepaid expenses and other current assets 292 86 Total current assets 19,161 48,039Right of use assets, net 38 262 Research and development incentive receivable, net of current portion 59 — Deposits 784 823 Total assets$ 20,042$ 49,124Liabilities and Stockholders' Equity Current liabilities: Accounts payable$ 7,339$ 4,743 Accrued expenses 6,623 8,536 Income tax payable 324 531 Lease liability - current portion 39 266 Total current liabilities 14,325 14,076 Stockholders' equity: Preferred stock, $0.001 par value; 10,000,000 shares authorized; 0 shares issued and outstanding as of June 30, 2025 and December 31, 2024, respectively — — Common stock, $0.001 par value; 240,000,000 shares authorized; 41,439,529 and 38,329,894 shares issued and outstanding as of June 30, 2025 and December 31, 2024, respectively 41 38 Additional paid-in capital 505,207 502,501 Accumulated other comprehensive loss (82) (120) Accumulated deficit (499,449) (467,371) Total stockholders' equity 5,717 35,048 Total liabilities and stockholders' equity $ 20,042$ 49,124 Leap Therapeutics, Inc. Condensed Consolidated Statements of Cash Flows (in thousands) (Unaudited) (Unaudited) Three Months Ended June 30 Six Months Ended June 30 20252024 20252024 Cash used in operating activities $ (14,486)$ (13,671) $ (28,966)$ (29,187) Cash provided by (used in) financing activities (119)37,117 (180)37,146 Effect of exchange rate changes on cash and cash equivalents 22112 27(123) Net increase (decrease) in cash and cash equivalents (14,583)23,558 (29,119)7,836 Cash and cash equivalents at beginning of period 32,71354,921 47,24970,643 Cash and cash equivalents at end of period $ 18,130$ 78,479 $ 18,130$ 78,479 View original content to download multimedia: SOURCE Leap Therapeutics, Inc. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data

Deere narrows full-year profit outlook; shares fall
Deere narrows full-year profit outlook; shares fall

Yahoo

time7 minutes ago

  • Yahoo

Deere narrows full-year profit outlook; shares fall

-- Deere & Company reported better-than-expected third-quarter results on Thursday, but shares fell 5% as the farm equipment manufacturer narrowed its full-year profit guidance amid ongoing market challenges. The agricultural machinery giant posted adjusted earnings of $4.75 per share for the quarter ended July 27, 2025, exceeding analyst expectations of $4.58. Revenue came in at $10.6 billion, above the consensus estimate of $10.35 billion, though still down 9% compared to the same period last year. Deere narrowed its full-year net income guidance to between $4.75 billion and $5.25 billion, compared to its previous forecast of $4.75 billion to $5.50 billion, reflecting continued caution about market conditions. The company cited customer hesitancy amid ongoing uncertainty in the agricultural sector. "By proactively managing inventory, we've matched production to retail demand, enabling our company and dealers to respond swiftly to market shifts and customer needs," said John May, chairman and CEO of John Deere. "By continuing to address the high levels of used equipment in the industry, we're building a healthier market for everyone." The company's Production & Precision Agriculture segment saw a 16% decline in sales and a 50% drop in operating profit compared to the same quarter last year. Small Agriculture & Turf sales decreased slightly by 1%, while Construction & Forestry sales fell 5%. Deere's financial services division was a bright spot, with net income increasing 34% to $205 million, driven by a lower provision for credit losses. Despite current challenges, the company remains focused on its technology offerings. "The increasing utilization and proven in-field effectiveness of advanced technologies—such as See & Spray and Harvest Settings Automation—are empowering customers to improve their productivity and better navigate industry challenges," May added. For fiscal 2025, Deere expects U.S. and Canada large agriculture equipment sales to decline approximately 30%, while small agriculture and turf equipment sales are projected to decrease around 10%. Related articles Deere narrows full-year profit outlook; shares fall Victoria's Secret Exposed: The Warning Sign Behind the Stock's 52% Collapse After soaring 149%, this stock is back in our AI's favor - & already +25% in July Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into a world of global content with local flavor? Download Daily8 app today from your preferred app store and start exploring.
app-storeplay-store